Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

Precision BioSciences, Inc. announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG.
[Precision BioSciences, Inc.]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News